Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
A phase 3 trial of Ribociclib and Exemestane in advanced solid tumours, run by Novartis Pharmaceuticals, now recruiting.
Overview
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer is a phase 3 interventional study registered as NCT05827081 by Novartis Pharmaceuticals, with 1400 participants planned, started 2024-02-28 and due to reach its primary completion in 2029-09-07. Interventions recorded: Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide and Exemestane.
Similar pages
not linked directly; found by shared links- TrialStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialRibociclib (LEE011) Rollover Study for Continued Access
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Shares Exemestane, Ribociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Shares Advanced Accelerator Applications (Novartis), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialSirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
Shares Exemestane, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Shares Ribociclib, Advanced Accelerator Applications (Novartis) and the tag pipeline.
- TrialTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
Shares Ribociclib, Metastatic cancer (cancer that has spread) and the tag pipeline.